tbuckley/cabot-search huggingface dataset:
Postoperative adjuvant chemoradiotherapy versus radiotherapy alone for head and neck squamous cell carcinoma: A meta-analysis evaluating the role of chemotherapy schedules.
Authors: G. A. Viani, S. L. Afonso, L. A. Ramos, V. Afonso, E. Stefano
Journal: Journal of Clinical Oncology (2010)

5583 Background: To compare concurrent post-operative chemoradiotherapy (POCRT) with post operative radiotherapy alone (PORT) for head and neck squamous cell carcinoma (HNSCC), evaluating different chemotherapy regimens used. Methods: A meta-analysis of RCT was performed comparing POCRT to PORT for HNSCC. The MEDLINE, EMBASE, and Cochrane Library databases, as well as abstracts published in the annual proceedings were systematically searched. We assessed methodological quality for each outcome by grading the quality of evidence using the Grading of Recommendations Assessment. Results: Pooled results from 8 randomized trials (1,808 patients) evaluating POCRT (3 trials using cisplatin alone, 2 mitomycin –c, 2 carboplatin and 1 cisplatin + 5-FU) in HNSCC showed significant decreased of mortality (OR=0.68, CI95%-0.52, 0.86, p<0.0001) as compared to PORT. In the subgroup analysis cisplatin alone was the only chemotherapy schedule that showed a reduction in overall mortality rate when compared to PORT (OR=0.62, CI95%-0.47, 0.82, p=0.0008). There was significant difference for local recurrence among those patients receiving PORCT and PORT (OR=0.46, CI 95% 0.37-0.58, p<0.0001). In the subgroup analysis the carboplatin schedule was the only subgroup that there was not any difference for local recurrence rates when compared to PORT (OR=0.72, CI 95% 0.46-1.13, p=0.25). Conclusions: Our data demonstrate that adjuvant cisplatin-enhanced radiation therapy is more effective than PORT for high-risk tumors in terms of locoregional control and survival, when compared to other regimens. Results of the present study failed to demonstrate that the addition of carboplatin to PORT provides a statistically significant benefit in terms of local control and survival rate. No significant financial relationships to disclose.
Acute Presentation of Tender Papules and Plaques in a Patient With Leukemia
Authors: Sandeep S. Saluja, Aaron M. Secrest, Scott R. Florell
Journal: JAMA Dermatology (2016)

A woman with acute myeloid leukemia was admitted with blast crisis and tumor lysis syndrome; flow cytometry showed myeloid blasts, most of which expressed CD13, CD33, CD117, and partial CD11b, and blasts were highly positive for myeloperoxidase. What is your diagnosis?
A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin: its application to the measurement of granulocyte-derived elastase digests in plasma
Authors: Isao Kohno, Kimiko Inuzuka, Yumiko Itoh, Kunihiko Nakahara, Yutaka Eguchi, Teruko Sugo, Gilbu Soe, Yoichi Sakata, Hideki Murayama, Michio Matsuda
Journal: Blood (2000)
Lung cancer in patients ≥ 80 years of age: Analysis of the national surveillance, epidemiology and end results (SEER) database
Authors: T. K. Owonikoko, C. Belani, C. Cai, A. Oton, D. Potter, S. Ramalingam
Journal: Journal of Clinical Oncology (2006)

7156 Background: Lung cancer is a disease of the elderly with median age at diagnosis of 70 years. In spite of this, the very elderly (patients ≥ 80 years) group has not been well studied. We analyzed the national SEER database to evaluate outcome of the disease in this subgroup. Methods: All patients with primary lung cancer in the national SEER database from 1988–1997 were included, and grouped into those &lt;80 yrs vs. those ≥80 yrs at the time of diagnosis. We compared the 2 groups for stage distribution, 3-yr &amp; 5-yr survival, survival based on histology, sex, race, stage and treatment. The 5-yr relative survival rate, adjusted for the normal life expectancy, was utilized except for the 3-yr survival comparison. The SEER program, Stat 6.1.4, was used for analysis and all p-values were 2-sided. Results: Of the 129,003 cases of lung cancer registered over 10 years, 14,614 (11%) occurred in patients ≥80 yrs. Overall survival at 3 and 5yrs was inferior in the octogenarian group, {11.8% vs. 20% and 8.3% vs. 16.2%, respectively (p &lt; 0.0001)}. The inferior survival was observed in both males and females {7.1% vs. 14.3% and 9.6% vs. 18.9%, respectively (p &lt; 0.0001)} and with non-small cell histology {9.1% vs. 18.3% (p &lt; 0.0001)}. Stage-specific analysis revealed the same trend {24.9% vs. 46.9% - stage I, 19.1% vs. 30.4% - stage II, 3.1% vs. 9.0% - stage III and 1.1% vs. 1.8% - stage IV (p &lt; 0.0001 for all comparisons)}. Irrespective of race, elderly patients fared worse: 6.9% vs. 12.8% in blacks, 8.4% vs. 16.7% in white and 8.4% vs. 16.3% in other racial groups (p &lt; 0.0001 for all comparisons). Although, therapy (surgery or radiation) benefited both groups, treated elderly group performed worse than younger group {4.9% vs. 8.1% (p &lt; 0.0001) and 45% vs. 45.7% (p &lt; 0.02) with radiation and surgery respectively}. However, only 58% of elderly patients received surgery or radiation therapy compared to 80% of patients &lt;80 yrs. Conclusion: In general, very elderly patients with lung cancer have a worse clinical outcome than younger patients. This is irrespective of histology, stage of disease, sex, gender or race. The worse outcome in the elderly may be due to a larger proportion of them not receiving treatment. No significant financial relationships to disclose.
Abstract 17052: Overexpression of Mitofilin in Mouse Heart Increases the ROS Level and Promotes Cardiac Hypertrophy
Authors: Yuan Zhang, Hou-Zao Chen, Yu-Xuan Luo, Rui-Feng Yang, Guang Liu, Li-Hong Sun, De-Pei Liu
Journal: Circulation (2012)

Background Mitofilin was originally described as heart muscle protein (HMP) because of its abundance in heart tissue, yet its function in the heart has not been investigated. Methods and Results A ...
Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Authors: N. W. Choong, E. E. Cohen, M. F. Kozloff, D. Taber, J. L. Wade III, S. Hu, S. P. Ivy, K. Nichols, A. Dekker, E. E. Vokes
Journal: Journal of Clinical Oncology (2008)

6064 Background: Sunitinib is an oral multitargeted tyrosine kinase inhibitor against RET, VEGFR, PDGFR, and c-KIT. We conducted a phase II trial to evaluate the tolerability and efficacy of sunitinib in metastatic and/or recurrent SCCHN patients. Methods: Patients who had received no more than two prior regimens were eligible and, depending on ECOG performance status (PS), were entered into either Cohort A (PS0–1) or Cohort B (PS2). Sunitinib was administered in 6-week cycles at 50mg daily for 4 weeks followed by 2 weeks off. Primary endpoints were objective tumor response and tolerability for Cohorts A and B, respectively. Results: Twenty-two patients were accrued (Cohort A - 15 pts, Cohort B - 7 pts). Median age in cohort 1 and 2 were 56 and 61 years, respectively. Grade 3/4 hematologic toxicities encountered were lymphopenia (18%), neutropenia (14%) and thrombocytopenia (9%). Fatigue and anorexia were the most common non-hematologic toxicities. Grade 3/4 fatigue occurred in 23% of pts. Vascular complications included hypertension (5pts), epistaxis (3pts), pulmonary hemorrhage (2pts), gastrointestinal hemorrhage (2pts) and tumor hemorrhage (1pt). Four patients were not evaluable for tumor response (Cohort A - 3pts, Cohort B - 1pt). In cohort A, out of the 12 evaluable patients, one partial response was observed and 3 pts attained disease stabilization. In cohort B, no objective tumor responses were observed but 2 pts attained disease stabilization in 6 evaluable pts. Dose reduction was required in 5pts. In Cohort B, 2pts required dose reduction for grd 3 fatigue and grd 3 nausea. Median follow-up was 10 weeks. Median time to progression for cohort A and B were 9 and 11 weeks, respectively. Median overall survival for cohort A and B were 21 and 19 weeks, respectively. Conclusions: Although sunitinib was well tolerated in PS 0–2 patient, efficacy parameters in cohort A were not met at interim analysis and the study was closed to accrual. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration National Institutes of Health
Effect of radium-223 dichloride (Ra-223) on pain from US EAP.
Authors: Michael J. Morris, A. Oliver Sartor, Nicholas J. Vogelzang, Neal D. Shore, Paul Cislo, Keith Bangerter, Christopher Sweeney
Journal: Journal of Clinical Oncology (2015)

160 Background: Ra-223, a first-in-class alpha-emitting radiopharmaceutical, has shown pain palliation in phase 2 trials (Parker 2013; Nilsson 2012). Here we present the results of Ra-223 effect on pain from US EAP. Methods: Pain was assessed at baseline, during treatment (trt) , and follow up (up to 6 mos after last trt visit) using the Brief Pain Inventory (BPI-SF) Questionnaire. The pain severity assessment was based on the worst pain item from the BPI-SF. The analysis was restricted to those not on opioids at baseline due to missing data for those on opioids. Hypotheses tests were based on changes from baseline. A meaningful change in score was defined as &gt;2 points from baseline (Atkinson 2010). Results: Of 177 treated patients (pts) with baseline pain scores, 109 were not on opioids at baseline (6% had a score of 0 [no pain], 46% had 1-4 [mild pain], 34% had 5-7 [moderate pain], 14% had 8-10 [severe pain]). A significant decrease in mean pain severity from baseline (P&lt;0.05) was observed at all trt visits. Among 97 pts who could have pain improvement (baseline score ≥2), 57 (59%) experienced a reduction in pain during at least one on-trt visit. Among all pts not on opioids at baseline and had baseline pain assessment, 46/109 (42%) had improved pain without worsening (decrease of ≥2 points), 20/109 (18%) had stable pain (no change of ≥2 points), 30/109 (28%) had worsening of pain (increase of ≥2 points or initiation of opioids) at some point and never had improvement, 11/109 (10%) had improvement and worsening at different times during trt, and 2/109 (2%) had no post baseline data. (Table presents data at each trt visit). Conclusions: Radium-223 was associated with meaningful pain relief in 42% of pts, whereas 28% had worse pain and 18% no change. The confounding effect of change in opioids after initiation prevents adequate interpretation of this finding for pts on opioids at baseline. Clinical trial information: NCT01516762. [Table: see text]
Reduced expression of miR-9 is associated with unfavorable characteristics of epithelial ovarian cancer
Authors: Lingeng Lu, Dionyssios Katsaros, Andrew Wiley, I. A. Rigault de la Longrais, Manuela Puopolo, Herbert Yu
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

1778 

MiRNAs are a group of noncoding RNAs of approximately 20-22 nucleotides in length, and they play important roles in the development, cell proliferation, and diseases. Aberrant miRNA expression has been previously reported in human cancers including lung, breast and chronic lymphocytic leukemias. Computational algorithm prediction indicates that putative targets of miR-9 and let-7 are insulin-like growth factor II mRNA binding proteins (IMPs), which control the expression and RNA trafficking of IGF-II that has been found to be associated with the poor prognosis of epithelial ovarian cancer in our previous studies. To evaluate the role of these miRNAs in epithelial ovarian cancer and their relationship with IGF-II, we used the Taqman® microRNA assay to measure the expressions of miR-9 and let-7 in 198 primary epithelial ovarian cancer tissues collected during surgical removal of the primary tumor prior to any chemotherapy or radiation, and analyzed miR-9 and let-7 expressions in relation to disease characteristics and patient survival. The results showed that miR-9 and let-7 expressions varied widely in epithelial ovarian cancer. The average expression of miR-9 was 0.38, and significantly lower than that of let-7 (median, 4.66) (p<0.001). The two miRNAs were positively correlated with each other (r=0.52, p<0.001). A weak inverse correlation was found between miR-9 and IGF-II expressions (r=-0.16, p=0.027). The levels of miR-9 were significantly lower in patients with large size of residual tumor and serous histology than those with small residual tumor and non-serous histology. There was a trend that lower miR-9 was associated with aggressive tumors. Patients with late stage disease, high tumor grade and suboptimal debulking tended to have low expression of miR-9. However, similar associations were not observed for let-7. Neither miR-9 nor let-7 was significantly associated with patient survival when analyzed with the Cox proportional hazard regression model. The unadjusted Cox regression analysis, however, did indicate that patients with high miR-9 had slightly better survival; the relative risk for disease progression was 0.71 (95% CI: 0.42-1.18) when patients with high tertile of miR-9 expression were compared to those with low tertile. Our study was the first to show that reduced miR-9 expression was associated with clinical and pathological features of ovarian cancer, suggesting that miRNA may be useful biomarkers for molecular characterization of cancer. Our study also indicates that further investigation of miRNA’s role in cancer is warranted.
Telomerase Is a Highly Sensitive and Specific Molecular Marker in Fine-Needle Aspirates of Breast Lesions
Authors: Christopher Poremba, Kenneth R. Shroyer, Michael Frost, Raihanatou Diallo, Franz Fogt, Karl-Ludwig Schäfer, Horst Bürger, A. Laurie Shroyer, Barbara Dockhorn-Dworniczak, Werner Boecker
Journal: Journal of Clinical Oncology (1999)

PURPOSE: Telomerase has been detected in a majority of human malignant tumors, making telomerase activity (TA) one key difference between mortal and immortal cells. In this study, we evaluated in blind-trial fashion the association of TA with cytologic and final clinical/pathologic diagnosis in fine-needle aspirates (FNAs) of breast lesions. MATERIALS AND METHODS: In 172 FNAs, including 80 samples that were cytologically malignant, 18 that were atypical but not diagnostic for malignancy, and 74 that were cytologically benign, TA was determined by a modified nonradioactive telomeric repeat amplification protocol (TRAP) assay. Final diagnosis was made by pathologic examination of follow-up surgical material available for all the cytologically malignant samples, a majority of the cytologically atypical samples, and a portion of the cytologically benign samples. RESULTS: TA was detected in 85 of 172 samples. Comparison of the cytologic and histologic diagnoseswith TA showed that 80 of 87 samples from patients with breast cancer were telomerase-positive, resulting in a sensitivity of 92%. TA was found in four of five FNAs from carcinomas that were considered cytologically atypical but not diagnostic for malignancy. Eighty of 85 samples from patients with benign breast lesions were telomerase-negative, revealing a specificity of 94%. The five positive cases in this group were all fibroadenomas with low TA. Among the 18 cases with a cytologic diagnosis of atypia, there was a strong positive relationship between TRAP findings and histologic diagnosis. CONCLUSION: The detection of TA in FNAs of breast lesions is a highly sensitive and specific marker of malignancy and may be used as an adjunct in cases with an equivocal cytologic diagnosis.
Processes as predictors of outcomes of EOL care at a VA medical center
Authors: M. L. Gonzalez, V. T. Chang, D. Hoover, M. U. Bhatty, S. K. Gounder, M. A. Sikder, H. V. Wu, J. Cogswell, B. Crump, B. S. Kasimis
Journal: Journal of Clinical Oncology (2008)

20646 Background: The objective of the study is to find quality indicators that predict outcomes of EOL care. Methods: Items from performance measures proposed by Earle et al (Int J Qual Health Care 2005;17:505) were used to develop multivariate logistic regression models for the outcomes 1) whether a patient enters into Hospice, 2) dies in an acute care institution, and 3) is admitted into the ICU within one month of death. We analyzed data from a cohort of veteran patients. Process variables included the type of underlying disease, whether pain or symptom medications were administered, whether psychological support was given, and whether patients were admitted to the MICU. Analyses were done with SAS. Conclusions: Supportive care measures, such as pain and symptom medications are associated with increased likelihood of entering Hospice, and support counseling increases the likelihood of dying in an acute care institution and being admitted to the ICU within the last month of life. These findings should be confirmed in other studies. Multivariate Predictors of Entering Hospice and Dying in an Acute Care Institution Pt entered hospice, OR Pt entered hospice, p Pt died in acute care institution OR Pt died in acute care, p Pt admitted to ICU, OR Pt admitted to ICU, p Age per year 0.96 0.001 0.99 0.78 0.97 0.01 Age per year 0.28 0.048 0.99 0.78 0.55 0.45 Hematologic malignancy vs others 0.28 0.048 13.7 0.007 0.55 0.45 Pain and Symptom Meds 10.5 0.042 1.72 0.73 Admit to ICU 0.17 0.004 9.72 0.001 Psychological support 0.58 0.15 4.22 0.005 4.96 0.01 DNR 1 week 0.45 0.08 3.06 0.029 No significant financial relationships to disclose.
A phase II trial of combination chemotherapy with irinotecan and amrubicin in pretreated patients with non-small cell lung cancer
Authors: Y. Segawa, N. Nogami, T. Shinkai, K. Kiura, M. Tabata, N. Takigawa, K. Hotta, T. Shibayama, H. Ueoka, M. Tanimoto
Journal: Journal of Clinical Oncology (2007)

18111 Background: Amrubicin, a totally synthetic anthracycline, is a topoisomerase II inhibitor and highly effective for non-small cell lung cancer (NSCLC) as a single agent with response rates of 25% to 28%. We previously conducted a phase I trial of combination chemotherapy with irinotecan and amrubicin for NSCLC and found acceptable toxicity profiles with a favorable efficacy in patients with pretreated NSCLC. The aim of this phase II trial was to further evaluate its efficacy and toxicity in this population. Methods: Primary endpoint was objective response. Patients with NSCLC previously treated with one or two chemotherapy regimens were enrolled in this trial. Irinotecan and amrubicin were both administered on days 1 and 8, every 3 weeks at doses of 100 and 40 mg/m 2 , respectively. Response and toxicity were assessed according to the RECIST guideline and NCI Common Terminology Criteria for Adverse Events v3.0. Results: Thirty-one pretreated NSCLC patients were enrolled between 2004 and 2006. A median number of courses administered was 3 (range: 1 to 6). All patients and courses were assessable for efficacy and safety. Demographics of the patients were as follows: M/F: 21/10, Ad/others: 21/10, ECOG-PS 0/1: 12/19, and smoker/non-smoker: 21/10. Platinum-based regimens were commonly used as the prior chemotherapy. Objective response was obtained in 9 of the 31 patients with a response rate of 29.0% (95%CI: 12.1–46.0%). Grade 4 leukopenia and neutropenia were observed in 6 (19%) and 14 (45%) patients, respectively, whereas thrombocytopenia were generally mild. Grade 3 febrile neutropenia was observed in 7 patients (23%), of whom two patients further developed Grade 4 and 5 septic shock each. Other grade 3 or greater non-hematological toxicities included diarrhea, vomiting, pneumonitis, liver dysfunction in 4, 1, 1 and 2 patients, respectively. At the time of this analysis with a median follow-up time in the surviving patients of 7.5 months, median survival time and median progression-free survival time were 11.9 and 4.0 months, respectively. Conclusion: This combination seemed highly effective for pretreated NSCLC despite the moderate toxicity profiles. Development of efficient patient selection is needed to avoid the serious toxicities. No significant financial relationships to disclose.
Cortical Cystic Necrosis in Wilson Disease
Authors: Aakash S. Shetty, Ritu Kashikar, Aabha Nagral, Pettarusp M. Wadia
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60–9
Authors: Stephen B. Williams, Ashish M. Kamat
Journal: European Urology (2016)
A Retrospective Analysis of Hodgkin Lymphoma: Clinical Features and Prognosis of 56 Cases in Our Institution
Authors: Akira Kojima, Yusuke Kanemasa, Shigeo Yamaguchi, Tatsu Shimoyama, Eisaku Sasaki, Yasushi Omuro, Rumiko Okamoto, Yoshiharu Maeda, Tsuneo Sasaki, Tsunekazu Hishima
Journal: Annals of Oncology (2014)
원발성 간세포암 환자에서 간동맥화학색전술 후 발생한 괴사성 간농양 및 담도괴사 1 예
Authors: 정규(Gyu Jung), 김정욱(Jeong Wook Kim), 조준형(Jun Hyung Joe), 김상진(Sang Jin Kim), 이종범(Jong Beum Lee), 김재규(Jae Gyu Kim), 박중원(Joong Won Park), 장세경(Sae Kyung Chang), 유병철(Byung Cheol Yoo), 박실무(Sil Moo Park)
Journal: Clinical and Molecular Hepatology (1999)

Transcatheter arterial chemoembolization (TACE) is widely used in the treatment of hepatocellular
carcinomas. We report a case of mult iple liver abscess with bile duct necrosis following gallbladder infarction after TACE in a patient with hepatocellular carcinoma. A 62- year old man, wit h four cm sized hepatocellular carcinoma in right lobe, was treat ed by TACE for six times during 18 months. Two days after the last TACE, acute cholecystitis occurred and antibiotics were used until the recovery of cholecystitis. After two months, abdominal CT scan revealed a gas containing liver abscess and percutaneous transhepatic drainage was performed. Cholangiography via drainage cathet er showed findings of bile duct necrosis. Ant ibiotics sensit ive to the causative organism were administered intravenously. However, the abscess persisted despite of treatment for three mont hs. (Korean J Hepatol 1999 ; 5 : 348－352)